Stéphane Bancel, Former bioMérieux CEO, Talks Future of Startups, Diagnostics, Pharma

Stéphane Bancel, Former bioMérieux CEO, Talks Future of Startups, Diagnostics, Pharma

August 4, 2011

Excerpted from Xconomy story:

Amid all the comings and goings and CEOs changing jobs in the past week—see Rick Reidy of Progress Software (NASDAQ: PRGS), Mara Aspinall of On-Q-ity, and others—one person flew under the radar in Boston.

Acceleron Pharma, Inc.

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program

August 3, 2011

SUMMIT, NJ and CAMBRIDGE, Mass.

Permeon Biologics Inc.

Permeon Biologics Announces Discovery of Human Intraphilin™ Proteins as a Novel Approach to Develop Intracellular Biologic Drugs

Permeon Biologics Announces Discovery of Human Intraphilin™ Proteins as a Novel Approach to Develop Intracellular Biologic Drugs

July 28, 2011

CAMBRIDGE, Mass., July 28, 2011 - Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins™. The sequence and structure of these naturally supercharged human proteins enable biologic drugs to penetrate and function inside of mammalian cells.

BG Medicine, Inc.

BG Medicine, Inc. Appoints Stephane Bancel as Executive Chairman of the Board

BG Medicine, Inc. Appoints Stephane Bancel as Executive Chairman of the Board

July 27, 2011

WALTHAM, Mass., July 27, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Stéphane Bancel, former CEO of bioMérieux (NYSE Euronext:BIM), has been appointed Executive Chairman of the Board of Directors. He has been a member of the BG Medicine Board since January 2010. Noubar Afeyan, a founder and Chairman of the Board since the company's inception, continues to serve on the board.

Joule Unlimited, Inc.

Joule Awarded Patents for High-Volume Ethanol Production from Sunlight and CO2

Joule Awarded Patents for High-Volume Ethanol Production from Sunlight and CO2

July 26, 2011

Cambridge, Mass. – July 26, 2011 – Joule Unlimited Technologies today announced the issuance of its first two U.S. patents covering its fundamental method for producing ethanol at volumes and efficiencies far surpassing biomass-dependent processes.

LS9

LS9 AND HCL CLEANTECH AWARDED A $9 MILLION GRANT FROM THE DEPARTMENT OF ENERGY

LS9 AND HCL CLEANTECH AWARDED A $9 MILLION GRANT FROM THE DEPARTMENT OF ENERGY

July 18, 2011

SOUTH SAN FRANCISCO, CA - July 18, 2011 - LS9 Inc., a technology leader in the development of sustainable products, today announced that it has been awarded in conjunction with partner HCL CleanTech Ltd., a $9 million grant from the Department of Energy (DOE) to improve and demonstrate an integrated process to convert biomass feedstocks into fermentable sugars and then into diesel and other fuel and chemical products.

Quanterix Corporation

Quanterix and Sony DADC to Develop and Manufacture Smart Consumables for Life Science and In Vitro Diagnostic Applications

Quanterix and Sony DADC to Develop and Manufacture Smart Consumables for Life Science and In Vitro Diagnostic Applications

July 20, 2011

CAMBRIDGE, MA and SALZBURG, Austria – July 20, 2011 – Quanterix Corporation, enabling a new generation of diagnostic tests based on the revolutionary Single Molecule Array (SiMoA™) technology, and Sony DADC Austria AG, today announced that they have entered into a collaboration for the development and manufacture of "smart consumables" for use in the life science and in vitro diagnostic (IVD) markets. Production of the Quanterix SiMoA Disc marks the first diagnostic consumable whose assay technology is based on optical disc formats by Sony DADC.

Affinnova, Inc.

The Boston Globe features Affinnova, "The perfect supermarket cereal aisle?"

The Boston Globe features Affinnova, "The perfect supermarket cereal aisle?"

July 15, 2011

At first glance, there would seem to be little overlap between algorithms developed for genetic research and the ways consumers shop for breakfast cereal, but Affinnova Inc., a Waltham company founded by two Massachusetts Institute of Technology PhDs, is making that connection.

In a recent press release, the market research technology firm disclosed that it was working on a project for Post Foods, which is known for such cereals as Grape-Nuts and Shredded Wheat, among many others.

Agios Pharmaceuticals, Inc.

Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer

Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer

July 14, 2011

Further Validates the Power of Agios’s Cancer Metabolism Research Capabilities

Pronutria Biosciences

Cambridge startup has tech to grow nutrients without farmland

Cambridge startup has tech to grow nutrients without farmland

July 13, 2011

One of the latest companies to come out of Flagship VentureLabs, Essentient Inc. of Cambridge, Mass., is working on an approach to producing nutrients for human consumption that doesn’t require arable land, Essentient CEO David Berry said in an interview.